Phenol

Phenol

SCHEMBL2774765

O=Cc1nccs1.Oc1ccccc1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIOK2 Q9BVS4 1/20 0.43
PDPK1 O15530 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
GLA P06280 1/20 0.39
CA3 P07451 1/20 0.39
CA4 P22748 1/20 0.39
CA9 Q16790 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CA14 Q9ULX7 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
AURKA O14965 1/20 0.38
PIM1 P11309 1/20 0.38
CDK2 P24941 1/20 0.38
GSK3B P49841 1/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
KDM4E B2RXH2 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28811 0.82
SCHEMBL506408 0.80
Hydrochloric Acid SCHEMBL4776707 0.80
Phenol SCHEMBL27468064 0.72 TDP1 (0.44) PDPK1CA12CA1CA2GLA
SCHEMBL949287 0.69 PDPK1 (0.45) RIOK2PDPK1TDP1NPC1RAB9A
SCHEMBL2283315 0.68 RIOK2 (0.50) RIOK2PDPK1NPC1RAB9AKMT2A
2-Thiophenenecarboxaldehyde SCHEMBL29079471 0.68 ABCG2 (0.49) CA12CA1CA2GLACA3
SCHEMBL2283312 0.68 RIOK2 (0.50) RIOK2PDPK1NPC1RAB9AKMT2A
SCHEMBL10552731 0.67
Phenol SCHEMBL662758 0.66 TDP1 (0.69) CA12CA1CA2GLACA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642324-B2 Methods of using heterocycle-amine ligands, compositions, complexes, and catalysts SYMYX SOLUTIONS, INC. (US) 2010-01-05 US disclosed
US-7642216-B2 Methods of using heterocycle-amine ligands, compositions, complexes, and catalysts SYMYX SOLUTIONS, INC. (US) 2010-01-05 US disclosed
US-20090143222-A1 METHODS OF USING HETEROCYCLE-AMINE LIGANDS, COMPOSITIONS, COMPLEXES, AND CATALYSTS SYMYX TECHNOLOGIES, INC. (US) 2009-06-04 US disclosed
US-20090131619-A1 METHODS OF USING HETEROCYCLE-AMINE LIGANDS, COMPOSITIONS, COMPLEXES, AND CATALYSTS SYMYX TECHNOLOGIES, INC. (US) 2009-05-21 US disclosed
US-7387980-B2 Methods of using heterocycle-amine ligands, compositions, complexes, and catalysts SYMYX TECHNOLOGIES, INC. 2008-06-17 US disclosed
US-7256296-B2 Heterocycle-amine ligands, compositions, complexes, and catalysts SYMYX TECHNOLOGIES, INC. (US) 2007-08-14 US disclosed
EP-1794196-A2 HETEROCYCLE-AMINE LIGANDS, COMPOSITIONS, COMPLEXES, AND CATALYSTS, AND METHODS OF MAKING AND USING THE SAME Symyx Technologies, Inc. (US) 2007-06-13 EP disclosed
US-20060094839-A1 Methods of using heterocycle-amine ligands, compositions, complexes, and catalysts SYMYX TECHNOLOGIES, INC. (US) 2006-05-04 US disclosed
US-20060094867-A1 Heterocycle-amine ligands, compositions, complexes, and catalysts SYMYX TECHNOLOGIES, INC. (US) 2006-05-04 US disclosed
WO-2006036748-A2 HETEROCYCLE-AMINE LIGANDS, COMPOSITIONS, COMPLEXES, AND CATALYSTS, AND METHODS OF MAKING AND USING THE SAME SYMYX TECHNOLOGIES, INC. (US) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094867-A1 Heterocycle-amine ligands, compositions, complexes, and catalysts PCNA, MYB, PNMT RIOK2 3055/4885PDPK1 1060/4885CA12 4548/4885
US-20060094839-A1 Methods of using heterocycle-amine ligands, compositions, complexes, and catalysts PCNA, PPOX, ODC1 RIOK2 3205/4885PDPK1 1300/4885CA12 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.